Table 2. Follow-up data and clinical outcome of IgAN patients enrolled.
| Follow-up data | |
|---|---|
| Duration of follow-up: median (IQ; years) | 4.7 (2.4–7.9) |
| TA-MAP (mm Hg) | 96±9 |
| TA-SBP (mm Hg) | 129±14 |
| TA-DBP (mm Hg) | 79±8 |
| Median number of antihypertensive drugs | 1.0 (0.8–2.0) |
| TA proteinuria (g/day) | 0.8 (0.4–1.6) |
| TA proteinuria <0.5, ⩾0.5 <1, ⩾1 <1.5, ⩾1.5 <2, ⩾2 (%) | 29, 28, 25, 9, 19 |
| Immunosuppression | |
| Oral corticosteroids (%) | 43 |
| Intravenous ‘pulse' methylprednisolone (%) | 16 |
| Other immunosuppression (%) | 16 |
| Any immunosuppression (%) | 46 |
| Nonimmunosuppressive treatments | |
| RASB (%) | 86 |
| Fish oil (%) | 13 |
| Tonsillectomy (%) | 5 |
| Clinical outcome data | |
| Rate of decline in renal function (ml/min per 1.73 m2/year) | −1.8±7.5 |
| 50% decrease in eGFR (%) | 14 |
| ESRD (<15 ml/min per 1.73 m2) (%) | 12 |
| 50% decrease in eGFR or ESRD (%) | 16 |
Abbreviations: DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; IgAN, IgA nephropathy; MAP, mean arterial blood pressure; RASB, renin–angiotensin system blockade; SBP, systolic blood pressure; TA, time average (see text for definition).
Results are expressed by mean±s.d., median (interquartile range), or percent as appropriate. Means and medians are time-averaged (see Materials and Methods).